NLRP3-mediated inflammation in cardio-oncology: sterile yet harmful

Area of Science:

• Cardio-oncology
• Molecular mechanisms of cardiotoxicity
• Inflammasome biology

Background:

• Cancer therapy-induced cardiotoxicity is a significant cause of morbidity and mortality, rivaling secondary malignancies.
• The field of cardio-oncology aims to enable effective cancer treatment with minimal cardiovascular risk.
• Multiple mechanisms contribute to cardiotoxicity, including oxidative stress, impaired autophagy, and sterile inflammation.

Purpose of the Study:

• To elucidate the principal mechanisms by which various cancer therapies induce cardiotoxicity, focusing on the NLRP3 inflammasome.
• To review evidence for cardio-protection using inflammasome inhibitors in general heart disease.
• To highlight the potential clinical translation of inflammasome inhibition for preventing cardiotoxicity in cancer patients.

Main Methods:

• Review of existing literature on cancer therapy mechanisms and cardiotoxicity.
• Focus on studies investigating the role of the NLRP3 inflammasome in cancer therapy-induced heart damage.
• Synthesis of evidence regarding inflammasome inhibitors and their cardioprotective effects.

Main Results:

• Several cancer therapies induce cardiotoxicity through pathways involving mitochondrial dysfunction, oxidative stress, and lysosomal damage.
• The NLRP3 inflammasome is a key mediator in sterile inflammation contributing to cancer therapy-induced cardiotoxicity.
• Evidence suggests inflammasome inhibitors may offer cardioprotection against various heart conditions.

Conclusions:

• The NLRP3 inflammasome plays a critical role in the cardiotoxicity associated with certain cancer therapies.
• Inflammasome inhibitors show promise as a strategy for cardio-protection in patients undergoing cancer treatment.
• Further clinical research is warranted to translate these findings into effective preventative strategies for cancer patients at risk of cardiovascular events.